Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Net Margin: 2011-2025

Historic Net Margin for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to 35.57%.

  • Catalyst Pharmaceuticals' Net Margin rose 147.00% to 35.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.54%, marking a year-over-year increase of 911.00%. This contributed to the annual value of 33.23% for FY2024, which is 1828.00% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Net Margin stood at 35.57%, which was up 0.05% from 35.55% recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Net Margin ranged from a high of 41.92% in Q4 2022 and a low of -29.96% during Q3 2023.
  • Its 3-year average for Net Margin is 27.70%, with a median of 34.64% in 2023.
  • Its Net Margin has fluctuated over the past 5 years, first slumped by 11,910bps in 2021, then soared by 6,406bps in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Net Margin stood at 24.30% in 2021, then surged by 1,762bps to 41.92% in 2022, then slumped by 2,115bps to 20.77% in 2023, then skyrocketed by 1,831bps to 39.09% in 2024, then skyrocketed by 147bps to 35.57% in 2025.
  • Its Net Margin was 35.57% in Q3 2025, compared to 35.55% in Q2 2025 and 40.12% in Q1 2025.